16th World Conference on Lung Cancer (WCLC) Presidential Symposium: Summary and Clinical Implications

Gilberto Lopes, MD, MBA


October 12, 2015

In This Article

Adjuvant Chemotherapy With or Without Bevacizumab

The second study, ECOG-ACRIN E1505,[5] a randomized prospective trial, evaluated the addition of bevacizumab, a monoclonal antibody that targets the VEGF and that is currently approved as part of the treatment of selected patients with advanced disease, to chemotherapy in the adjuvant setting for patients with NSCLC. Patients with resected stage IB—tumors bigger than 4 cm in diameter—to IIIB disease were randomly assigned to receive four cycles of chemotherapy alone or with the addition of bevacizumab for a year. Chemotherapy doublets in this trial included combinations of cisplatin with vinorelbine, docetaxel, gemcitabine, or pemetrexed. OS was the primary endpoint.

Between 2007 and 2013, a total of 1501 patients enrolled in the study. Approximately 15% were ineligible, and 2% did not start study treatment. With a median follow-up of 41 months and balanced baseline characteristics, the trial was negative. There were no significant differences in OS (HR=0.99; 95% CI, 0.81-1.21; P=.93) or PFS (HR=0.98; 95% CI, 0.84-1.14; P=.75). As such, chemotherapy alone continues to be the standard adjuvant treatment for patients with resectable lung cancer.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.